Loading...
The serotypes and antimicrobial susceptibility patterns of streptococcus pneumoniae in the Cape Peninsula
Author(s)
Scholtz, Janet
Date Issued
2000
Type
Thesis
Publisher
Cape Technikon
Abstract
Streptococcus pneumoniae (S.pneumoniae) infections are an important cause of
morbidity and mortality in adults and children worldwide. Mortality rates are highest
amongst the very young and the elderly. Streptococcus pneumoniae is the most
common form of community acquired bacterial pneumonia. Other diseases commonly
caused by Streptococcus pneumoniae include meningitis, pericarditis, bacteraemia and
septicaemia. Penicillin is today still consid3red the drug of choice when treating
pneumococcal infections. The emergence of resistant pneumococcal strains has made
it necessary to adapt antimicrobial regimens when treating pneumococcal infections.
Hansman (1967) reported the first penicillin resistant strain, which was isolated from a
woman in Australia in 1967. Since then penicillin and multi-resistant Streptococcus
pneumoniae strains have been observed worldwide, including South Africa.
Streptococcus pneumoniae infections may be caused by anyone of the 84 serotypes
recognized to date. The distribution of serotypes varies, depending on geographical
area, age and site of infection. High-level penicillin resistance and multiple resistant
Streptococcus pneumoniae strains have been recognised worldwide in a few
pneumococcal serotypes. Pneumococcal vaccines have been used since the seventies.
These capsular polysaccharide vaccines are generally recommended for at risk
population such as the elderly and immunocompromised patients. This vaccine is not
effective in children under 2 years old. The current vaccine in South Africa (Pneumovax,
MSD) consists of purified capsular polysaccharides of 23 pneumococcal serotypes.
Conjugated polysaccharide vaccines have been developed to overcome the problems
of efficacy in children < 2 years old. These vaccines consist of a capsular
polysaccharide linked to a protein carrier, which makes them immunogenic in infants.
Clinical trials of these vaccines are currently under way to demonstrate safety, efficacy
and immunogenicity.
Knowledge of serotype distribution and antimicrobial susceptibility patterns are
important in relation to the treatment of pneumococcal diseases and vaccination
programmes.
morbidity and mortality in adults and children worldwide. Mortality rates are highest
amongst the very young and the elderly. Streptococcus pneumoniae is the most
common form of community acquired bacterial pneumonia. Other diseases commonly
caused by Streptococcus pneumoniae include meningitis, pericarditis, bacteraemia and
septicaemia. Penicillin is today still consid3red the drug of choice when treating
pneumococcal infections. The emergence of resistant pneumococcal strains has made
it necessary to adapt antimicrobial regimens when treating pneumococcal infections.
Hansman (1967) reported the first penicillin resistant strain, which was isolated from a
woman in Australia in 1967. Since then penicillin and multi-resistant Streptococcus
pneumoniae strains have been observed worldwide, including South Africa.
Streptococcus pneumoniae infections may be caused by anyone of the 84 serotypes
recognized to date. The distribution of serotypes varies, depending on geographical
area, age and site of infection. High-level penicillin resistance and multiple resistant
Streptococcus pneumoniae strains have been recognised worldwide in a few
pneumococcal serotypes. Pneumococcal vaccines have been used since the seventies.
These capsular polysaccharide vaccines are generally recommended for at risk
population such as the elderly and immunocompromised patients. This vaccine is not
effective in children under 2 years old. The current vaccine in South Africa (Pneumovax,
MSD) consists of purified capsular polysaccharides of 23 pneumococcal serotypes.
Conjugated polysaccharide vaccines have been developed to overcome the problems
of efficacy in children < 2 years old. These vaccines consist of a capsular
polysaccharide linked to a protein carrier, which makes them immunogenic in infants.
Clinical trials of these vaccines are currently under way to demonstrate safety, efficacy
and immunogenicity.
Knowledge of serotype distribution and antimicrobial susceptibility patterns are
important in relation to the treatment of pneumococcal diseases and vaccination
programmes.
Additional information
Thesis (Masters Diploma(Technology))--Cape Technikon, Cape Town, 2000
File(s)![Thumbnail Image]()
Loading...
Name
The Serotypes and and Antimicrobial Susceptibility Patterns of Streptococcus Pneumoniae.pdf
Size
9.76 MB
Format
Adobe PDF
Checksum
(MD5):446c76b49ea6d8486e81287684cf254d